Quel est le prix pour National Graphite Corp. (NGRC)

Le prix pour National Graphite Corp. (NGRC) est $0.021

Quelle est la capitalisation boursière pour National Graphite Corp. (NGRC)

La capitalisation boursière pour National Graphite Corp. (NGRC) est $3.24M

National Graphite Corp. (NGRC) Rendement du Dividende

National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.

Année	Rendement du dividende	Changez
Pas assez de données pour les dates fournies.

Année

Rendement du dividende

Changez

Pas assez de données pour les dates fournies.

Entreprise	Rendement du dividende	Pays
Clone Algo Technologies Inc. CATI.US	0.00%	US
Worldwide Webb Acquisition Corp. WWAC.US	0.00%	US
Gushen, Inc. GSHN.US	0.00%	CN
Apollo Strategic Growth Capital APSG.US	0.00%	US
Digital World Acquisition Corp. DWAC.US	0.00%	US

Entreprise

Rendement du dividende

Pays